ATHE NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Alterity Therapeutics Ltd · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 4.45 USD
0.8% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 9.2% above the Trend Line and sits at 55.4% of its 52-week range. The latest completed week returned 0.8%, after a -18.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 60/100. Near-term considerations: volume confirmation is below normal; earnings are due in 14d.

Setup score 32 out of 100
Latest Close 4.45 USD 7 Aug 2026
1W Return 0.8% latest completed week
4W Return -18.0% short-term follow-through
12W Return 10.4% quarterly tape
Trend Breadth 44.2% 23 of 52 weeks active
Volume Ratio 0.1x vs 13-week average
What is working
  • The trend backdrop is active with a 14-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 37.47% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.8% Latest completed week; four-week move -18.0%. Indicator stack 69/44 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 37.47% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 60/100 44 relevant articles in the latest sentiment read. Event risk 14d Next report is scheduled for 27 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 9.2% above the Trend Line and sits at 55.4% of its 52-week range. The latest completed week returned 0.8%, after a -18.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.1x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5712-week average 0.50

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.57Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -18.0% over four weeks, 10.4% over 12 weeks, and -17.6% over one year. The current trend has remained active for 14 consecutive weeks.

Performance by holding period

1W0.8%
4W-18.0%
12W10.4%
26W26.1%
52W-17.6%
Active trend streak14 weeks
Active weeks in one year23
Trend breadth44.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.06Latest activity-pressure read.
Pressure change-94.8%Four-week change in activity pressure.
Leadership-4.38Latest relative-leadership reading.
RS change-136.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 74%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength74/100Blend of value, momentum, and quality. Underlying universe rank 27; rank 1 is best.
Value62/100Relative valuation strength. Underlying universe rank 39; rank 1 is best.
Quality60/100Profitability and accounting quality. Underlying universe rank 41; rank 1 is best.
Momentum62/100Medium-term price momentum. Underlying universe rank 39; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
14.8x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-24.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
97.7%
Gross profit retained from each unit of revenue.
Operating margin
-269.6%
Operating profit retained from revenue.
Free-cash-flow margin
-143.6%
Free cash flow generated from revenue.
Return on invested capital
-213.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-77.5%
Net share repurchases relative to market value.
Shareholder yield
-77.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
3.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment60/100

Weighted news tone is positive across 44 relevant articles.

14 positive · 28 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings14dNext report is scheduled for 27 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-24.5%Distance below the 52-week high.
13-week volatility7.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+20.3%Week of 17 Apr.
Worst week-13.5%Week of 15 May.
Latest week+0.8%Week of 7 Aug.

Shape of recent returns

Strong gains9
Modest gains3
Flat weeks0
Modest losses8
Sharp losses6
Recent vol7.9%13-week weekly-return volatility.
Base vol7.9%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew7.3% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape37/100

Trend, activity pressure, participation, and risk combine to a 37/100 tape read.

 Indicator analysis73/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 5/12.

Activity pressure 0.57; No reversal markers Next-Week ExpectancyNegative 37.47%

Next-week expectancy is negative with a 37.47% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors64/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 99; Small Cap Core rank 46 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment60/100

Weighted news tone is positive across 44 relevant articles.

Alterity Therapeutics CEO to Present at 46th Annual Canaccord Genuity Growth Conference Insiders50/100

No recent insider transaction evidence is stored.

 Earnings14d

Next report is scheduled for 27 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20264.45 USD0.8%4.07 USD3.11 USD0.06-4.3812.3KOn
31 Jul 20264.42 USD-2.8%4.04 USD3.10 USD0.49-1.2721.6KOn
24 Jul 20264.54 USD-8.8%4.00 USD3.09 USD0.901.2886.2KOn
17 Jul 20264.98 USD-8.3%3.96 USD3.08 USD1.157.7574.6KOn
10 Jul 20265.43 USD1.3%3.89 USD3.07 USD1.1712.0374.8KOn
3 Jul 20265.36 USD11.2%3.82 USD3.05 USD1.0612.32166.8KOn
26 Jun 20264.82 USD-1.2%3.76 USD3.04 USD0.771.88120.6KOn
19 Jun 20264.88 USD15.9%3.72 USD3.02 USD0.70-1.60110.8KOn
12 Jun 20264.21 USD7.9%3.67 USD3.01 USD0.68-13.191.7MOn
5 Jun 20263.90 USD-5.3%3.66 USD3.00 USD0.73-18.3271.5KOn
29 May 20264.12 USD-0.5%3.64 USD3.00 USD1.06-18.39104.5KOn
22 May 20264.14 USD2.7%3.65 USD2.99 USD1.21-16.3693.3KOn
15 May 20264.03 USD-13.5%3.66 USD2.98 USD1.34-18.19165.9KOn
8 May 20264.66 USD-1.4%3.69 USD2.97 USD1.42-6.22110.7KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context